Vargatef, known generically as nintedanib, is a medication primarily used in the treatment of idiopathic pulmonary fibrosis (IPF) and certain types of non-small cell lung cancer (NSCLC), particularly in cases where the disease is locally advanced, metastatic, or if other therapies have failed. It operates as a tyrosine kinase inhibitor, targeting multiple pathways involved in tumor growth, angiogenesis (the formation of new blood vessels that tumors need to grow), and fibrosis (the thickening and scarring of connective tissue). By inhibiting these processes, Vargatef can slow the progression of the disease and help manage symptoms. It is usually administered in capsule form and taken orally. Like all medications, it can cause side effects, and its use must be carefully monitored by a healthcare professional to ensure its benefits outweigh any potential risks.